06.29.12
Long Beach, CA
562.628.1007
www.obagi.com
Sales: $114 million.
Net income: $10 million.
Key Personnel: Albert F. Hummel, president, director and chief executive officer; Preston S. Romm, chief financial officer and executive vice president of finance; David S. Goldstein, executive vice president, global sales and field marketing; Laura B. Hunter, vice president, general counsel and secretary.
Major Products: Dermatologist-based skin care systems including Nu-Derm, Professional-C, Elastiderm, Obagi-C Rx, Clenziderm and Rosaclear.
New Products: Elastiderm Eye Complete Complex Serum
Comments: Based on a 2011 study by Kline & Co., Obagi is the leading skin health company in the physician-dispensed channel, with an estimated 30.1% market share, nearly two times the market share of the next largest competitor.
Obagi systems and products are designed to prevent and improve the most common and visible skin disorders in adult skin, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Products are sold through a direct sales force in the US and internationally through distribution partners in more than 43 countries across North America, Central America, Europe, the Middle East and Asia.
This year, for the second year in a row, Obagi Medical Products was named as the “The Best Skin-Care System at a Doctor’s Office” by New Beauty magazine.
“We are honored to be named, once again, the top skin care system from a physician’s office,” said Jim Hartman, vice president of global marketing and business development at Obagi Medical Products. “Being acknowledged in 2011 and now in 2012, by consumers, along with such an esteemed group of beauty insiders and industry professionals, makes it that much more significant.”
In 2013, The Obagi Nu-Derm System turns 25. It was launched in 1988 and consists of a combination of six prescription, OTC therapeutic agents and adjunctive cosmetic skin care products to treat visible skin conditions such as photodamage and hyperpigmentation resulting from extrinsic damage and intrinsic changes to the skin.
The Obagi Nu-Derm System accounted for approximately 53% of net sales for the year ended Dec. 31, 2011, according to the company.
562.628.1007
www.obagi.com
Sales: $114 million.
Net income: $10 million.
Key Personnel: Albert F. Hummel, president, director and chief executive officer; Preston S. Romm, chief financial officer and executive vice president of finance; David S. Goldstein, executive vice president, global sales and field marketing; Laura B. Hunter, vice president, general counsel and secretary.
Major Products: Dermatologist-based skin care systems including Nu-Derm, Professional-C, Elastiderm, Obagi-C Rx, Clenziderm and Rosaclear.
New Products: Elastiderm Eye Complete Complex Serum
Comments: Based on a 2011 study by Kline & Co., Obagi is the leading skin health company in the physician-dispensed channel, with an estimated 30.1% market share, nearly two times the market share of the next largest competitor.
|
Obagi’s topselling Nu-Derm range is turning 25 next year. |
This year, for the second year in a row, Obagi Medical Products was named as the “The Best Skin-Care System at a Doctor’s Office” by New Beauty magazine.
“We are honored to be named, once again, the top skin care system from a physician’s office,” said Jim Hartman, vice president of global marketing and business development at Obagi Medical Products. “Being acknowledged in 2011 and now in 2012, by consumers, along with such an esteemed group of beauty insiders and industry professionals, makes it that much more significant.”
In 2013, The Obagi Nu-Derm System turns 25. It was launched in 1988 and consists of a combination of six prescription, OTC therapeutic agents and adjunctive cosmetic skin care products to treat visible skin conditions such as photodamage and hyperpigmentation resulting from extrinsic damage and intrinsic changes to the skin.
The Obagi Nu-Derm System accounted for approximately 53% of net sales for the year ended Dec. 31, 2011, according to the company.
